HLVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HLVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
HilleVax does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.
The historical rank and industry rank for HilleVax's Owner Earnings per Share (TTM) or its related term are showing as below:
HilleVax's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.97. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.30. It's PE Ratio ratio for today is At Loss.
HilleVax's EPS without NRI for the three months ended in Mar. 2024 was $-0.65. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.98. It's PE Ratio without NRI ratio for today is At Loss.
The historical data trend for HilleVax's Owner Earnings per Share (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Owner Earnings per Share (TTM) | - | - | - | - |
HilleVax Quarterly Data | ||||||||||||||
Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Owner Earnings per Share (TTM) | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, HilleVax's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, HilleVax's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where HilleVax's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
To make it simple, then you will have:
Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)
HilleVax does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.
Be Aware
Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.
Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.
Thank you for viewing the detailed overview of HilleVax's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.
Astrid Borkowski | officer: Chief Medical Officer | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109 |
Nanette Cocero | director | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109 |
Shane Maltbie | officer: Chief Financial Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Frazier Life Sciences X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Fhmls X, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Gary Dubin | director | C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109 |
Jaime Sepulveda | director | C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109 |
Takeda Vaccines, Inc. | 10 percent owner | 75 SIDNEY STREET, CAMBRIDGE MA 02139 |
Shelley Chu | director | ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110 |
Susan Michele Silbermann | director | C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540 |
Fhmls X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101 |
Julie L. Gerberding | director | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Aditya Kohli | director, officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089 |
David A Socks | officer: CFO & Chief Business Officer | C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
From GuruFocus
By sperokesalga sperokesalga • 03-17-2023
By GuruFocus Research • 12-06-2023
By Value_Insider Value_Insider • 12-05-2022
By Ds*** Ds*** • 09-01-2022
By PurpleRose PurpleRose • 07-20-2022
By PurpleRose PurpleRose • 08-10-2022
By GlobeNewswire GlobeNewswire • 09-01-2022
By Ds*** Ds*** • 08-31-2022
By Marketwired • 09-19-2023
By GuruFocusNews GuruFocusNews • 05-03-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.